Changing Natural History of HER2–Positive Breast Cancer Metastatic to the Brain in the Era of New Targeted Therapies
Louisa A. Mounsey(Massachusetts General Hospital), Carey K. Anders(Duke University), Shlomit Strulov Shachar(Tel Aviv Sourasky Medical Center), Lisa A. Carey(University of North Carolina at Chapel Hill), Allison M. Deal(Memorial Sloan Kettering Cancer Center), Matthew G. Ewend, Kevin Keith(Medical University of South Carolina), Timothy M. Zagar(University of North Carolina at Chapel Hill), Julia M. Benbow(University of North Carolina at Chapel Hill), Elizabeth Claire Dees(University of North Carolina at Chapel Hill)
Cited by 42
Related Papers
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
The molecular portraits of breast tumors are conserved across microarray platforms
|BMC Genomics|2006|1.5k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k